ESPR Esperion Therapeutics Inc.

Esperion to Participate in January Investor Meetings

Esperion to Participate in January Investor Meetings

ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the Company plans to present at the J.P. Morgan 41st Annual Healthcare Conference as well as the LifeSci Partners 12th Annual Corporate Access Event. Both in-person events are taking place January 9-11th, 2023 in San Francisco, California.

J.P. Morgan 41st Annual Healthcare Conference

Sheldon Koenig, CEO, will be making a corporate presentation and hosting 1x1 institutional investor meetings.

Date/Time: January 11th, 2023, 1:30pm PT

Location: The Westin St. Francis Hotel in San Francisco; Georgian Room

Click to access the webcast.

LifeSci Partners 12th Annual Corporate Access Event

Sheldon Koenig, CEO, Ben Halladay, CFO, and JoAnne Foody, CMO, will be hosting 1x1 institutional investor meetings.

Date/Time: January 9-10th, 2023

Location: Beacon Grand Hotel in San Francisco

To schedule a meeting on the online system managed by LifeSci Partners, please click to register for the conference.

Esperion Therapeutics

Esperion works hard to make our medicines easy to get, easy to take, and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit and follow us on Twitter at /EsperionInc.

Contact:

Esperion Corporate Communications



EN
13/12/2022

Underlying

ESPREsperion Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Announces Pricing of Public Offering of Common Stock

Esperion Announces Pricing of Public Offering of Common Stock ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a public offering price of $2.50 per share. In addition, Esperion has granted the underwrit...

October 8, 2025 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Announces Proposed Public Offering of Common Stock

Esperion Announces Proposed Public Offering of Common Stock ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced that it has commenced an underwritten public offering of shares of its common stock. Esperion also intends to grant the underwriters a 30-day option to purchase up to an additional fif...

October 7, 2025 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Lab...

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories, Inc. and its affiliate Dr. Reddy’s Laboratories Ltd. (together, Dr. Reddy’s Laboratories). This agreement resolves the patent litigation brought by Esperion against Dr. Reddy’s Laboratories in response to Dr. Redd...

October 3, 2025 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETO...

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® (bempedoic acid) tablets in Japan, has received approval from the Japanese Ministry of Health, Labour and Welfare to market NEXLETOL...

September 19, 2025 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ...

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias – Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence – – Guideline Recognition of ‘Strike Early and Strike Strong’ Approach with Early Combination Lipid-Lowering Therapy Affirms Continued Development of Company’s Oral Triple Combination Therapies in U.S. – ANN ARBOR, Mich., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today welcomed the inclusion of bempedoic acid as the only n...

August 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch